•
Dec 31, 2023

CryoPort Q4 2023 Earnings Report

Reported financial results for the fourth quarter and full year 2023.

Key Takeaways

Cryoport reported full year revenue of $233.3 million. The services business increased to 62% of total revenue, with year-over-year growth in BioStorage/BioServices and support of commercial Cell & Gene therapies of 45% and 33%, respectively. The company supported a record 675 clinical trials worldwide.

Total revenue for FY 2023 was $233.3 million.

Services business increased to 62% of total revenue.

Revenues from BioStorage/BioServices grew 45% year-over-year.

Supported 675 global clinical trials, a net increase of 21 clinical trials over the prior year.

Total Revenue
$57.3M
Previous year: $60.4M
-5.1%
EPS
-$0.3
Previous year: -$0.24
+25.0%
Gross Profit
$23.3M
Previous year: $26.3M
-11.5%
Cash and Equivalents
$457M
Previous year: $523M
-12.7%
Free Cash Flow
-$9.09M
Previous year: -$4.2M
+116.3%
Total Assets
$958M
Previous year: $1.04B
-7.8%

CryoPort

CryoPort

CryoPort Revenue by Geographic Location

Forward Guidance

The Company is expecting revenue to grow progressively and is providing full year 2024 revenue guidance of $242 - $252 million.